Table 1 Patient baseline and disease characteristics
Variable | Navoximod 21/28 days BID | Navoximod 28/28 days BID | All patients (n = 22) | |||||
|---|---|---|---|---|---|---|---|---|
|  | 50 mg (n = 1) | 100 mg (n = 3) | 200 mg (n = 3) | 400 mg (n = 3) | 600 mg (n = 3) | 800 mg (n = 6) | 600 mg (n = 3) |  |
Age (yr), median (range) | 65 (65-65) | 58 (50-82) | 63 (32-75) | 54 (41-69) | 58 (27-59) | 69 (38-70) | 67 (43-72) | 61 (27-82) |
Sex | ||||||||
 Female | 1 (100%) | – | 3 (100%) | 3 (100%) | 3 (100%) | 3 (50%) | 2 (67%) | 15 (68%) |
 Male | – | 3 (100%) | – | – | – | 3 (50%) | 1 (33%) | 7 (32%) |
ECOG performance status | ||||||||
 0 | 1 (100%) | 1 (33%) | 3 (100%) | – | 1 (33%) | 1 (17%) | 2 (67%) | 9 (41%) |
 1 | – | 2 (67%) | – | 3 (100%) | 2 (67%) | 5 (83%) | 1 (33%) | 13 (59%) |
Most common tumor types | ||||||||
 Colorectal | – | – | – | 2 (67%) | – | 4 (67%) | – | 6 (27%) |
 Head and neck | – | – | 1 (33%) | 1 (33%) | – | 1 (17%) | – | 3 (14%) |
 Leiomyosarcoma | – | 1 (33%) |  | – | – | – | 1 (33%) | 2 (9%) |
 Lung | – | 1 (33%) | 1 (33%) | – | – | – | – | 2 (9%) |
 Pancreas | – | – | 1 (33%) | – | 1 (33%) | – | – | 2 (9%) |
 Renal | – | – | – | – | 1 (33%) | 1 (17%) | – | 2 (9%) |
 Bladder | 1 (100%) | – | – | – | – | – | – | 1 (5%) |
 Breast | – | – | – | – | – | – | 1 (33%) | 1 (5%) |
 Cholangiocarcinoma | – | 1 (33%) | – | – | – | – | – | 1 (5%) |
 Mesothelioma | – | – | – | – | – | – | 1 (33%) | 1 (5%) |
 Testicular | – | – | – | – | 1 (33%) | – | – | 1 (5%) |
Number of prior systemic therapies, median (range)a | 5 (5-5) | 4 (1-5) | 3 (1-3) | 4 (3-4) | 3 (2-9) | 3.5 (2-6) | Â | Â |